This perspective highlights the need for an inclusive regulatory definition and touches upon some fundamental crystal-engineering aspects and considerations useful for the design and development of pharmaceutical co-crystals.
No takes yet. Share an insight, caveat, or question.
Khazir et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: